Efficacy and Safety of Allopurinol on Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis

Author:

Sharbaf Fatemeh Ghane1,Bakhtiari Elham2,Faghihi Toktam3,Assadi Farahnak4

Affiliation:

1. Department of Pediatrics, Division of Nephrology (FGS), Mashhad University of Medical Sciences, Mashhad, Iran

2. Clinical Research Development (EB), Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3. Department of Clinical Pharmacy (TF), School of Medicine, Tehran University of Medical Sciences, and Pediatric Center of Excellence, Children’s Medical Center, Tehran, Iran

4. Department of Pediatrics, Division of Nephrology (FA), Rush University Medical Center, Chicago, IL

Abstract

OBJECTIVE Hyperuricemia is associated with the progression of chronic kidney disease (CKD). Whether urate-lowering treatment with allopurinol can delay disease progression remains controversial. METHODS Relevant databases were searched. Randomized clinical trials comparing the efficacy and ­safety of allopurinol in patients with CKD were selected. The primary outcomes were changes in serum uric acid concentration and estimated glomerular filtration rate (eGFR). Random-effects modeling was used to ­calculate the standard mean difference (SMD) with 95% CIs. RESULTS Four trials enrolling 698 participants were included. All were 2-arm parallel trials with a mean duration follow-up of 22.5 months. Congenital anomalies of the kidney and urinary tract were the most common cause of CKD in children, whereas diabetes was the leading cause of CKD in adults. Allopurinol significantly increased the eGFR compared with control groups (SMD, 2.04; 95% CI, 0.60–3.49; p = 0.005; I2 = 98.23%). Allopurinol led to a significant decrease in serum uric acid concentration compared with the control group (SMD, −5.16; 95% CI, −8.31 to −2.01; p = 0.001; I2 = 98.80%). No significant difference in adverse effects was identified between treatment and control groups. CONCLUSIONS Allopurinol treatment in patients with CKD and hyperuricemia slows the decline in eGFR as compared with placebo, without risk of increased adverse effects.

Publisher

Pediatric Pharmacy Advocacy Group

Reference43 articles.

1. Longitudinal changes in uric acid concentration and their relationship with chronic kidney disease progression in children and adolescents;Schwatrz;Pediatr Nephrol,2023

2. Uric acid lowering therapies for prevention or delaying the progression of chronic kidney disease;Sampson;Cochrane Database Syst Rev,2017

3. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOWCKD study;Oh;Sci Rep,2019

4. Hyperuricemia and associated factors in children with chronic kidney disease: a cross-sectional study;Xu;Children (Basel),2022

5. Serum uric acid and risk of CKD in type 2 diabetes;De Cosmo;Clin J Am Soc Nephrol,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3